Shizuoka Sencha Green Tea (Camellia sinensis 'Shizuoka Sencha')

Shizuoka Sencha is a Japanese green tea cultivar (Camellia sinensis) grown in Shizuoka Prefecture, rich in the catechin epigallocatechin gallate (EGCG), which scavenges free radicals and inhibits LDL lipid peroxidation. Its bioactive polyphenols interact with oxidative stress pathways, offering antioxidant and potential cardiovascular protective effects supported primarily by in vitro evidence.

Origin & History

Shizuoka Sencha is a cultivar variant of Camellia sinensis green tea produced in Japan's Shizuoka Prefecture, benefiting from volcanic ash soil rich in potassium, phosphorus, and magnesium (pH 4.5-5.5). The tea is made from steamed and rolled young leaves without oxidation, a process that preserves higher catechin levels compared to shaded teas like Gyokuro or Matcha.

Historical & Cultural Context

Green tea from Camellia sinensis, including Japanese Sencha variants, has been used in Traditional Chinese and Japanese medicine for centuries as a refreshing beverage with purported antioxidant and neuroprotective effects. Shizuoka's production leverages natural soil advantages without heavy chemical inputs.

Health Benefits

• Antioxidant activity: EGCG demonstrates DPPH radical scavenging (EC50 0.03-0.10 mol/mol) in vitro studies, though human trials lacking
• LDL protection: Catechins inhibit LDL lipid peroxidation at 0.1 μg/mL in vitro, but no human clinical evidence provided
• Mineral supplementation: Contains 92-151 mg/L potassium and 35-69 mg/L sodium in infusions, though clinical significance unstudied
• Polyphenol content: Provides 117-442 mg/L EGCG and 203-471 mg/L EGC in standard infusions, but bioavailability data incomplete
• Traditional support: Historically used for antioxidant and neuroprotective effects, though specific clinical trials for Shizuoka variant absent

How It Works

EGCG (epigallocatechin gallate), the dominant catechin in Shizuoka Sencha, donates hydrogen atoms to neutralize DPPH and hydroxyl free radicals with an EC50 of 0.03–0.10 mol/mol in vitro, functioning as a chain-breaking antioxidant. At concentrations as low as 0.1 μg/mL, catechins intercalate into LDL phospholipid membranes and inhibit copper-mediated lipid peroxidation by chelating pro-oxidant metal ions and scavenging peroxyl radicals. Additionally, EGCG modulates NF-κB signaling and downregulates pro-inflammatory cytokines such as TNF-α and IL-6, though these pathways have not been confirmed in robust human trials for this specific cultivar.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses were found for Shizuoka Sencha itself; all evidence pertains to general green tea studies. The research references Shizuoka University studies on catechin bioavailability and cardiovascular links but provides no trial specifics, sample sizes, or PMIDs.

Clinical Summary

Current evidence for Shizuoka Sencha specifically is limited to in vitro assays; no cultivar-specific randomized controlled trials have been published. Broader green tea catechin research includes meta-analyses of 14–17 RCTs (n=1,000–2,000 participants) showing modest LDL reductions of 2–5 mg/dL with daily EGCG intakes of 200–400 mg. Observational data from Japanese cohort studies (e.g., Ohsaki cohort, n=40,530) associate habitual green tea consumption with reduced cardiovascular mortality, though causality is unconfirmed. The antioxidant and mineral supplementation claims for this cultivar rely on compositional analysis and extrapolation from general Camellia sinensis research, making the strength of evidence preliminary.

Nutritional Profile

Shizuoka Sencha Green Tea infusion (per 100 mL brewed at 70-80°C, 2g/200mL): Macronutrients are negligible — calories ~1-2 kcal, protein <0.1g, carbohydrates <0.1g, fat 0g. Key bioactive compounds: Total catechins 120-180 mg/100mL, comprising EGCG (epigallocatechin gallate) 60-90 mg/100mL (dominant catechin, ~50-60% of total), EGC (epigallocatechin) 15-30 mg/100mL, ECG (epicatechin gallate) 10-25 mg/100mL, EC (epicatechin) 8-15 mg/100mL. L-theanine 20-45 mg/100mL (umami-associated amino acid, bioavailability ~95% oral absorption). Caffeine 20-35 mg/100mL. Chlorophyll 3-8 mg/100mL (shaded early-harvest leaves increase this). Vitamin C (ascorbic acid) 5-12 mg/100mL, partially degraded at steeping temperatures above 80°C. Vitamin B2 (riboflavin) ~0.01 mg/100mL. Minerals per 100mL infusion: potassium 92-151 mg, sodium 35-69 mg, magnesium 2-4 mg, calcium 1-3 mg, manganese 0.3-0.5 mg, fluoride 0.1-0.3 mg. Total polyphenols 150-220 mg GAE/100mL. Bioavailability notes: EGCG oral bioavailability is low (~1-5%) due to intestinal efflux and colonic degradation; fasting consumption increases absorption ~3-fold. L-theanine crosses the blood-brain barrier efficiently. Catechin absorption is reduced by milk protein binding. Shizuoka region's volcanic soil contributes to elevated mineral content compared to other Japanese sencha cultivars.

Preparation & Dosage

No clinically studied dosage ranges are specified for Shizuoka Sencha. Standard infusions provide 117-442 mg/L EGCG, 203-471 mg/L EGC, and 141-338 mg/L caffeine. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-theanine, vitamin C, quercetin, zinc, selenium

Safety & Interactions

Shizuoka Sencha is generally well tolerated at typical beverage intakes (2–4 cups/day, ~100–300 mg EGCG), but high-dose EGCG supplements (>800 mg/day) have been associated with hepatotoxicity in case reports and clinical trials. The caffeine content (approximately 20–40 mg per 200 mL serving) may interact with adenosine receptor antagonism, potentiate stimulant medications, and elevate blood pressure or heart rate in sensitive individuals. EGCG can inhibit intestinal absorption of iron by forming insoluble complexes, reducing non-heme iron bioavailability by up to 25%; individuals with iron-deficiency anemia should consume Sencha away from iron-rich meals. Pregnant and breastfeeding women should limit intake due to caffeine exposure and potential interference with folate metabolism mediated by EGCG inhibition of dihydrofolate reductase.